Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma Topic Center

Industry Insights
News

news


News
Real-World Study Reveals Shifting Treatment Patterns and Persistent Unmet Needs in DLBCL
10/29/2026
Hannah Musick
A real-world US study found that novel therapies are increasingly replacing conventional treatments for diffuse large B-cell lymphoma (DLBCL), although declining survival outcomes across successive lines of therapy and substantial variation...
A real-world US study found that novel therapies are increasingly replacing conventional treatments for diffuse large B-cell lymphoma (DLBCL), although declining survival outcomes across successive lines of therapy and substantial variation...
A real-world US study found that...
10/29/2026
First Report Managed Care
News
Liso-Cel May Offer Greater Cost-Effectiveness Than Axi-Cel in LBCL
10/26/2026
Hannah Musick
A US cost-effectiveness analysis projected that lisocabtagene maraleucel could provide modest quality-adjusted survival gains and lower lifetime treatment costs compared with axicabtagene ciloleucel as second-line therapy for relapsed or...
A US cost-effectiveness analysis projected that lisocabtagene maraleucel could provide modest quality-adjusted survival gains and lower lifetime treatment costs compared with axicabtagene ciloleucel as second-line therapy for relapsed or...
A US cost-effectiveness analysis...
10/26/2026
First Report Managed Care
News
Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
News
GemOx-Based Combination Shows Improved Outcomes in Patients With R/R DLBCL
04/28/2026
Grace Taylor, MS, MA
An indirect comparison shows epcoritamab plus gemcitabine and oxaliplatin (Epcor+GemOx) significantly improves response and survival outcomes over standard therapy in transplant-ineligible patients with relapsed or refractory diffuse large...
An indirect comparison shows epcoritamab plus gemcitabine and oxaliplatin (Epcor+GemOx) significantly improves response and survival outcomes over standard therapy in transplant-ineligible patients with relapsed or refractory diffuse large...
An indirect comparison shows...
04/28/2026
First Report Managed Care
News
Lowering Levels of cFLIP Expression Could Improve Extrinsic Apoptosis in DLCBL
04/27/2026
Rebecca Amrick
A study used an autochthonous mouse model to observe how cFLIP expression affects the development of cancerous cells in diffuse large B-cell lymphoma (DLBCL).
A study used an autochthonous mouse model to observe how cFLIP expression affects the development of cancerous cells in diffuse large B-cell lymphoma (DLBCL).
A study used an autochthonous...
04/27/2026
First Report Managed Care
News
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
04/20/2026
Grace Taylor, MS, MA
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study,...
04/20/2026
First Report Managed Care
News
Glofitamab Shows Cost Savings for R/R DLBCL Treatment in the US
04/08/2026
Grace Taylor, MS, MA
Glofitamab may reduce overall treatment costs in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), offering US payers a lower-cost alternative to existing third-line therapies.
Glofitamab may reduce overall treatment costs in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), offering US payers a lower-cost alternative to existing third-line therapies.
Glofitamab may reduce overall...
04/08/2026
First Report Managed Care
News
Glofitamab Plus Polatuzumab Shows Strong Responses in R/R LBCL
03/31/2026
Grace Taylor, MS, MA
Glofitamab plus polatuzumab vedotin delivered high response rates and durable outcomes in heavily pretreated relapsed or refractory large B-cell lymphoma (R/R LBCL), including high-risk subgroups and prior chimeric antigen receptor (CAR)...
Glofitamab plus polatuzumab vedotin delivered high response rates and durable outcomes in heavily pretreated relapsed or refractory large B-cell lymphoma (R/R LBCL), including high-risk subgroups and prior chimeric antigen receptor (CAR)...
Glofitamab plus polatuzumab...
03/31/2026
First Report Managed Care
News
Long-Term Follow-up Confirms Durable Responses With Epcoritamab in R/R LBCL
03/30/2026
Lisa Kuhns, PhD, MD
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab...
03/30/2026
First Report Managed Care
News
CAR T-Cell Therapy and Bispecific Antibodies Diverge in Relapsed or Refractory DLBCL
03/25/2026
Hannah Musick
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory...
03/25/2026
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
What’s Next for Chronic Kidney Disease Treatment and Access
10/22/2026
Roy Moore
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging...
10/22/2026
First Report Managed Care
PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
Pipeline Projections
Examining Newly FDA-Approved Anticoagulants and Upcoming Drugs in the Approval Pipeline
02/12/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline...
02/12/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use